Penrose TherapeuTx

Penrose TherapeuTx is a private U.S. oncology biotech developing small-molecule therapies for difficult-to-treat cancers. The company is built around its Mitochondrial Modifying Agent (MMA) platform, which is designed to exploit cancer-cell mitochondrial vulnerabilities and drive metabolic collapse and necrotic cell death. Penrose has described applicability across both solid tumors and hematologic malignancies, with its lead program RP-0320 highlighted as the most advanced asset. Publicly available information indicates the company remains preclinical and focused on translating its mitochondrial biology approach into novel cancer therapeutics. The company has been associated with operations in Michigan and Boston and has built a leadership team with prior pharma and oncology development experience.